eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
vol. 23
Original paper

The endogenous erythropoietin in correlation with other erythrocytic parameters in patients with head and neck squamous cell carcinoma treated with platinum-based induction chemotherapy

Dominika Leś
Maria Saduś-Wojciechowska
Tomasz Rutkowski
Andrzej Wygoda
Krzysztof Składowski

I Department of Radiotherapy and Chemotherapy, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Gliwice, Poland
Department of Bone Marrow Transplantation and Haematology-Oncology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Gliwice, Poland
Contemp Oncol (Pozn) 2019; 23 (3): 178-182
Online publish date: 2019/10/31
Article file
- The endogenous.pdf  [0.07 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Cisplatin is one of the cytostatic agents that most frequently (47–100%) causes anaemia through erythropoietin (EPO) production damage. This is, in most cases, mild anaemia. Anaemia is a negative prognostic factor for patients with cancer because it causes tumour hypoxia, which leads to chemotherapy and radiotherapy resistance, genetic instability, resistant clone selection, apoptosis impairment, and angiogenesis stimulation. This facilitates disease progression and formation of distant metastases, and in consequence leads to a negative prognosis.

EPO is a glycoprotein peptide hormone stimulating various erythropoiesis stages in bone marrow. It is produced in kidneys (80%) and in liver (approximately 20%). Hypoxia stimulates kidney interstitial cells to produce EPO.

At a sufficient iron reserve, the stimulation of erythroblastic system by EPO appears as an increase in the total count of reticulocytes (REC), an increase in the percentage of their immature fraction (IFR) = MFR (medium-mature reticulocytes fraction of medium fluorescence) + HFR (immature reticulocytes fraction of high fluorescence), and an increase in haemoglobin concentration in reticulocytes (HGB-REC).

Over the last decade, preclinical data has revealed that EPO is not only the hormone that regulates erythropoiesis but is also a cytokine with a pleiotropic activity affecting cancer cells.

EPO and its receptor expression (EPO-R) has been found in many cancers of various origins. The EPO/EPO-R arrangement is active in many cancer cells and it takes part in the modification of molecular signal tracks and the stimulation of growth, survival, mobility, and ability to form metastases. EPO may increase the resistance of cancer cells to chemotherapy and radiotherapy. The impact of EPO on the tumour cells depends on a carcinoma type, expression level and EPO-R function in the cells of a specific carcinoma, micro-environment (hypoxia), and the type of administered anti-carcinoma treatment (both synergistic and antagonistic activity).

The aim of the study was to evaluate the concentrations of EPO in correlation with other erythrocytic parameters in the blood of patients with advanced head and neck squamous cell carcinoma (HNSCC) treated with platinum-based induction chemotherapy.

Material and methods

Between January 2017 and December 2018, 103 patients with HNSCC, treated with platinum-based induction chemotherapy, were qualified for prospective EPO monitoring (Tables 1 and 2).

Table 1

Characteristics of 103 patients who received platinum-based chemotherapy

DiagnosisOropharynx cancerNasopharynx cancerOral cavity cancerLarynx cancerUnknown primary cancerHypopharynx cancerNasal cavity cancerSalivary gland cancer
Number of patients33143078641
Table 2

Clinic stage

Tumour size (T)T4T3T2T1T0
Number of patients502114108
Lymphatic glands (N)N3N2N1N0
Number of patients19611013

The most common adverse effects of cisplatin were as follows: anaemia, nephrotoxicity, ototoxicity, and polyneuropathy. Therefore, the inclusion criteria for patients into the treatment comprised: good overall condition (ZUBROD < 2), Hb concentrations > 9 g/dl, glomerular filtration rate (GFR) > 60 ml/min and normal creatinine values, lack of hearing loss over one degree according to Common Terminology Criteria for Adverse Events (CTCAE), and lack of polyneuropathy above grade one according to CTCAE. Wilcoxon signed-rank test was used in statistical calculations.

All patients received from one to four cycles of induction chemotherapy based on the following patterns: TPF (docetaxel 75 mg/m2 on day 1, cisplatin 75 mg/m2 on day 1, 5-fluorouracil 750 mg/m2 on day1-5), PF (cisplatin 100 mg/m2 on day 1, 5-fluorouracil 1000 mg/m2 on day 1–4), carboplatin according to AUC 5 on day 1 + 5 fluorouracil (5 Fu) 1000 mg/m2 on day 1–4, carboplatin according to AUC 5 + paclitaxel (PXL) 175 mg/m2, PAC (cisplatin 50 mg/m2, cyclophosphamide 500 mg/m2, doxorubicin 50 mg/m2), or cisplatin 100 mg/m2 (Table 3). In about 20% (22) of patients there was a delay in the administration of cycle 2 or 3, generally due to neutropaenia of at least grade 2 according to CTCAE.

Table 3

Number of treatment cycles

Number of chemotherapy cyclescycle 1cycles 2cycles 3Over 3 cycles
Number of patients725656

EPO concentration in plasma and erythrocytic parameters: REC, HGB-REC, erythrocytes (RBC), Hb, MFR, HFR, IFR (IFR = MFR + HFR), and LFR (mature reticulocytes fraction of low fluorescence) were measured in the following points: before cycle 1 of chemotherapy, on day 11 of cycle 1, before cycle 2, on day 11 of cycle 2, before cycle 3, on day 11 of cycle 3, and after three cycles of chemotherapy.

Endogenic EPO was measured in blood serum by enzyme-labelled chemiluminescent immunometric assay, using an Immulite 2000XPi analyser before the administration and on day 11 of each chemotherapy cycle.


The analysis involved 103 patients who received from one to four cycles of induction chemotherapy.

Initial (i.e. before chemotherapy/initiation of treatment) EPO levels were at the lower limit or even below the normal range (4.3–29.0 mIU/ml), median: 8.4 and mean: 10.15. During induction chemotherapy, EPO levels increased in all the patients (Table 4).

Table 4

The levels of endogenous erythropoietin (EPO) during platinum-derivative-based induction chemotherapy in patients with advanced head and neck squamous cell carcinoma

EPOEPO1 (n = 92) before cycle 1EPO2 (n = 81) on day 11 of cycle 1EPO3 (n = 73) before cycle 2EPO4 (n = 67) on day 11 of cycle 2EPO5(n = 55) before cycle 3EPO6 (n = 41) on day 11 of cycle 3EPO7 (n = 20) after 3 cycles
Median8.40 (min 1.3 max 101 mIU/ml)10.70 (min 2.9 max 40.5 mIU/ml)10.90 (min 3.3 max 104 mIU/ml)14.35 (min 1.5 max 81.6 mIU/ml)14.95 (min 4.6 max 156 mIU/ml)17.00 (min 8.1 max 134 mIU/ml)20.90 (5.1 max 96.6 mIU/ml)
Mean ±SD10.15 ±10.6413.34 ±7.7413.68 ±12.1818.96 ±13.7220.35 ±20.8723.57 ±20.3426.65 ±22.48

Iron (Fe) metabolism parameters were determined in all the patients. In most cases there was chronic disease anaemia. Patients did not require supplementation of Fe preparations. Supplementation was conducted only in the case of Fe deficiency anaemia, in approximately 5% of cases (generally due to the tumour haemorrhage).

Differences between EPO1 and EPO2, EPO3 and EPO4, and EPO5 and EPO6 were statistically significant.

The EPO increase was found in a considerable number of patients in the middle of each chemotherapy cycle and then returning towards the initial values before the administration of subsequent treatment cycles.

In the analysed group, there was an increase in creatinine value (up to 107 mmol/l in one patient); creatinine concentrations were correct in the remaining patients. Eighty-nine patients (80%), after finishing induction chemotherapy, were treated radically. In the case of the remaining 14 patients (20%), due to the lack of any response to induction chemotherapy, palliative treatment was administered. There was rapid disease recurrence or dissemination among 28 patients treated radically (27%).

Initial erythrocytic parameters

Before chemotherapy, with a lack of anaemia, higher EPO concentrations stimulate REC production, but this is not reflected in the HGB and RBC concentration increase, and consequently it leads to anaemia accompanying cancer (92 cases). During platinum-based chemotherapy, EPO concentration growth can be observed (Table 5).

Table 5

Correlation analysis – the impact of three months’ chemotherapy based on platinum derivatives on the erythropoietin (EPO) concentration and erythrocytic parameters in patients with head and neck carcinoma

ParameterEPO1 (n = 92) before cycle 1 n = 92EPO2 (n = 81) on day 11 of cycle 1 n = 29EPO3 (n = 73) before cycle 2; no correlationEPO4 (n = 67) on day 11 of cycle 2 n = 32EPO5 (n = 55) before cycle 3; no correlationEPO6 (n = 41) on day 11 of cycle 3 n = 35EPO7(n = 20) after 3 cycles n = 14
EPO8.96 ±5.4411.83 ±7.1618.82 ±16.4523.55 ±22.4320.60 ±17.55
RBC4.64 ±0.48–0.39*4.47 ±0.51–0.43*4.19 ±0.43–0.40*3.96 ±0.40–0.46*4.01 ±0.44–0.71*
REC#64.91 ±20.9875.64 ±31.69
81.61 ±36.6481.73 ±47.3587.36 ±32.93
Hb13.98 ±1.28–0.44*13.36 ±1.57–0.50*12.79 ±1.1412.13 ±1.18–0.36*12.26 ±1.07
IRF9.73 ±4.70
13.57 ±6.62
17.70 ±10.25
17.97 ±8.2217.30 ±7.55
HGB-REC32.81 ±2.2633.63 ±2.2133.70 ±2.1334.79 ±2.8533.41 ±4.59

[i] Correlation coefficients labelled with an asterisk are significant at p < 0.05

  1. The administration of one chemotherapy dose results in higher EPO release (two-fold increase in EPO concentration), which intensifies REC production but without HGB-REC growth. In consequence, it leads to the decrease in RBC and HGB concentration (29–32 cases).

  2. The administration of two and three chemotherapy doses results in the subsequent increase of EPO release, which does not intensify REC production. In consequence, anaemia increases (35 cases).


  1. Platinum-based chemotherapy results in the increase of EPO concentration.

  2. The EPO concentration increase, despite the symptoms of erythroblastic system stimulation, does not lead to the prevention of carcinoma-related anaemia, which progresses probably due to platinum toxicity.


The endogenous EPO concentration during induction chemotherapy based on platinum derivatives in patients with advanced HNSCC is variable. At the time of chemotherapy lasting from one to three cycles, the EPO concentration increases; probably it takes place within a few days after the administration of cytotoxic agents.

Fe is retained in macrophages as a result of the stimulation of the immunological system by pro-inflammatory factors and carcinoma cells, leading to the activation of monocytes and lymphocytes and the production of TNF-α and interleukins in chronic diseases anaemia accompanying cancer. Their presence affects the production of acute-phase protein and hepcidin. Fe is retained in the reticuloendothelial system, which leads to the limitation of its availability for progenitor cells, which in turn causes erythropoiesis in the conditions of Fe deficiency.

Pro-inflammatory and anti-inflammatory cytokines variously affect the Fe uptake by macrophages. TNF-α induces erythrophagocytosis through the stimulation of proper receptors on macrophages, which destroy erythrocytes, shortening their survival time. In consequence, the Fe level lowers and Fe deficiency leads to the limitation of erythropoiesis and anaemia development. The route of releasing Fe from macrophages is also blocked – IFN-γ disrupts the ferroportin expression on monocytes, which causes excessive Fe retention in such cells. The concentration of available Fe is not sufficient for erythropoiesis. In addition, α-1-antitrypsin, forming a bond with free receptors for transferrin (TfR), blocks Fe availability for progenitor cells, disabling their growth and diversification. It leads to the impairment of proliferation and diversification of erythroid cells.

The conducted correlation analysis of EPO and erythrocytic parameters clearly demonstrated a strong correlation between the concentrations of EPO, IFR, and REC. Nevertheless, the EPO growth is not reflected in an HGB-REC increase in all patients.

The measurement of haemoglobin content in reticulocytes provides the possibility of evaluating Fe availability for the needs of erythropoiesis and evaluating the quality of newly-produced erythrocytes. It enables the detection of changes in the haemoglobin level significantly earlier than the measurement of haemoglobin content in mature erythrocytes.

The main advantage of the RET-HGB parameter, with reference to ferritin and transferrin, is that it is not dependent on the acute phase state. RET-HGB is used in monitoring EPO therapy and/or Fe intravenous therapy. When the value increases, it indicates a positive response.

Receptors for EPO occur on early progenitor cells of erythropoiesis – burst forming unit-erythroid (BFU-E) cells. Their density grows in colony forming unit-erythroid (CFU-E) cells and drops along the subsequent maturity of erythroblasts. However, they are not present in the cell membrane of reticulocytes and erythrocytes.

The sign of EPO activity is an increase in the division and proliferation of CFU-E cells and consequently HFR and MFR, which, in a physiological situation, causes the growth in the erythrocytes count. In our patients there was no increase in the erythrocytes count because we used ineffective erythropoiesis. The gradual drop in RBC and HGB level observed in patients was caused by myelotoxicity of platinum-derivatives (mainly cisplatin), but other cytostatic agents also fulfilled their role here. This may explain the nephrotoxicity of platinum compounds because cisplatin damages the kidney interstitial cells where EPO is produced. Usually, as in our study, this is mild anaemia.

In the available literature [119], among patients with lowered HGB level and correct creatinine level, a gradual increase in EPO value could be observed as well (only among patients under chemotherapy based on platinum) from the first to the last chemotherapy cycle and an increase in EPO concentration after nearly every chemotherapy cycle based on platinum (in particular, an increase in the middle of each cycle, which is probably caused by higher sensitivity of a mechanism responsible for EPO release after platinum injection, and then a drop towards the initial level before administering another cycle). Kidney efficiency was not related to EPO production.

The study presented includes various interpretations of EPO increase after cytostatic agent treatment:

  1. cytostatic therapy, while damaging directly the cells producing EPO in kidneys, imitates their hypoxia,

  2. inhibiting the activity of a bone marrow stimulates unknown factors for EPO production,

  3. decreasing erythrocytes precursors disturbs the regular route of EPO degradation.

The observed RBC and HGB level decrease was caused by:

  1. direct myelotoxicity of platinum compounds and other administered cytostatic agents,

  2. nephrotoxicity of platinum compounds that damage interstitial kidney cells where EPO is produced.

High fluctuations in EPO-R level through EPOR induction on HNSCC cells may stimulate the proliferation of tumour cells resistant to induction chemotherapy. This may cause disease progression/recurrence even if, after induction chemotherapy, disease regression was obtained.


Summarising – cyclic fluctuations of EPO concentration during induction chemotherapy and the successive increase in EPO level during treatment was observed.

The group of patients with post-treatment progression of disease should be analysed separately. So far, a group of 42 patients was analysed with post-treatment disease progression. High fluctuations of EPO level and an overall EPO increase were observed in this group. In those with peaks and general high increase in EPO concentration, rapid recurrences, distant metastasis or treatment failure can be expected. Such fluctuations may induce EPO-R in HNSCC cells and stimulate proliferation of clonogenic cells resistant to induction chemotherapy even if there is significant or complete regression after induction treatment.

On the basis of the available literature, we know that EPO may stimulate the growth, ability for metastasis, and drug resistance in cell lines of head and neck carcinoma. These preliminary results should be confirmed in further studies.


[2] Conflicts of interest The authors declare no conflict of interest.



Radziwon P, Krzakowski M, Kalinka-Warzocha E, Zaucha R, Wysocki P, Kowalski D, Gryglewicz J, Wojtukiewicz MZ , authors. Niedokrwistość u chorych na nowotwory. Oncol Clin Pract. 2017. 13:p. 202–210


Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A , authors. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001. 61:p. 3561–3565


Riley RS, Ben-Ezra JM, Goel R, Tidwell A , authors. Reticulocytes and reticulocyte enumeration. J Clin Lab Anal. 2001. 15:p. 267–294


Szenajch J, Synowiec A , authors. Erythropoietin and drug resistance in breast and ovary cancer. Ginekol Pol. 2016. 87:p. 300–304


Elliott S, Busse L, Bass MB, et al. , authors. Anti-Epo antibodies do not predict Epo receptor expression. Blood. 2006. 107:p. 1892–1985


Brown WM, Maxwell P, Graham AN, Yakkundi A, Dunlop EA, Shi Z, Johnston PG, Lappin TR , authors. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells. 2007. 25:p. 718–722


Della Ragione F, Cucciolla V, Borriello A, Oliva A, Perrotta S , authors. Erythropoietin receptors on cancer cells: a still open question. J Clin Oncol. 2007. 25:p. 1812–1813


Chretien S, Moreau-Gachelin F, Apiou F, et al. , authors. Putative oncogenic role of the erythropoietin receptor in murine and human erythroleukemia cells. Blood. 1994. 83:p. 1813–1821


Migliaccio AR, Bruno M, Migliaccio G , authors. Evidence for direct action of human biosynthetic (recombinant) GM-CSF on erythroid progenitors in serum-free culture. Blood. 1987. 70:p. 1867–1871


Arcasoy MO, Edgar BA, Harris KW, Forget BG , authors. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood. 1997. 89:p. 4628–4635


Vaupel P, Mayer A, Höckel M , authors. Impact of hemoglobin levels on tumor oxygenation: The higher, the better? Strahlenther Onkol. 2006. 182:p. 63–71


Arcasoy MO , author. Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives. Clin Cancer Res. 2008. 14:p. 4685–4690


Hadland BK, Longmore GD , authors. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J Clin Oncol. 2009. 27:p. 4217–4226


Fender J , author. Erythropoietin receptors on tumor cells: what do they mean? Oncologist. 2008. 13:p. 16–20


Swift S, Ellison AR, Kassner P, McCaffery I, Rossi J, Sinclair AM, Begley CG, Elliott S , authors. Absence of functional EpoR expression in human tumor cell lines. Blood. 2010. 115:p. 4254–4263


Sinclair AM, Coxon A, McCaffery I, et al. , authors. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood. 2010. 115:p. 4264–4272


Kirkeby A, Van BJ, Nielsen J, Leist M, Helboe L , authors. Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor. J Neurosci Methods. 2007. 164:p. 50–58


Laugsch M, Metzen E, Svensson T, Depping R, Jelkmann W , authors. Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer. 2008. 122:p. 1005–1011


Canapro R, Casale F, Muntoni E, et al. , authors. Plasma erythropoetin concentrations in patients receiving intensive platinum or non-platinum chemotherapy. Br J Pharmacol. 2000. 50:p. 146–153

Copyright: © 2019 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe